Alteraciones metabólicas asociadas al uso de terapia antipsicótica

The advent of new antipsychotic drugs has improved the treatment of schizophrenic patients as well as those suffering from other severe psychiatric disorders. Its widespread use, however, has been associated to the development of obesity and metabolic disturbances such as diabetes mellitus, dyslipid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rojas G,Paula, Poblete A,Catalina, Orellana G,Ximena, Rouliez A,Karen, Liberman G,Claudio
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2009
Materias:	Antipsychotic agents Insulin resistance Metabolic cardiovascular syndrome
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100017
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872009000100017
record_format	dspace
spelling	oai:scielo:S0034-988720090001000172009-04-13Alteraciones metabólicas asociadas al uso de terapia antipsicóticaRojas G,PaulaPoblete A,CatalinaOrellana G,XimenaRouliez A,KarenLiberman G,Claudio Antipsychotic agents Insulin resistance Metabolic cardiovascular syndrome The advent of new antipsychotic drugs has improved the treatment of schizophrenic patients as well as those suffering from other severe psychiatric disorders. Its widespread use, however, has been associated to the development of obesity and metabolic disturbances such as diabetes mellitus, dyslipidemia and increased coronary risk. This has caused a serious concern, due to the high cardiovascular mortality that prematurely affects these patients. The etiology of these abnormalities is still a matter of debate, although it is generally believed that the new antipsychotic drugs have a control stimulating effect on appetite, and their use is associated to an increased level of cortisol and to an insulin-resistance state. In addition, there is an increase in inflammatory mediator and cytokine production, induced by the pathophysiology of the schizophrenic process itself and also caused by the direct action of the antipsichotic drugs. In spite of the mounting evidence, the metabolic management of these patients is still deñcient. A cióse follow-up in the initial stages of the antipsychotic treatment is recommended, as well as giving advice about diet and physical exercise. Finally, when obesity or other conditions associated to metabolic syndrome appear, the recommendation is to switch to drugs with less secondary effects or to add adjuvant medications to improve the overall evolution of these patients.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.137 n.1 20092009-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100017es10.4067/S0034-98872009000100017
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antipsychotic agents Insulin resistance Metabolic cardiovascular syndrome
spellingShingle	Antipsychotic agents Insulin resistance Metabolic cardiovascular syndrome Rojas G,Paula Poblete A,Catalina Orellana G,Ximena Rouliez A,Karen Liberman G,Claudio Alteraciones metabólicas asociadas al uso de terapia antipsicótica
description	The advent of new antipsychotic drugs has improved the treatment of schizophrenic patients as well as those suffering from other severe psychiatric disorders. Its widespread use, however, has been associated to the development of obesity and metabolic disturbances such as diabetes mellitus, dyslipidemia and increased coronary risk. This has caused a serious concern, due to the high cardiovascular mortality that prematurely affects these patients. The etiology of these abnormalities is still a matter of debate, although it is generally believed that the new antipsychotic drugs have a control stimulating effect on appetite, and their use is associated to an increased level of cortisol and to an insulin-resistance state. In addition, there is an increase in inflammatory mediator and cytokine production, induced by the pathophysiology of the schizophrenic process itself and also caused by the direct action of the antipsichotic drugs. In spite of the mounting evidence, the metabolic management of these patients is still deñcient. A cióse follow-up in the initial stages of the antipsychotic treatment is recommended, as well as giving advice about diet and physical exercise. Finally, when obesity or other conditions associated to metabolic syndrome appear, the recommendation is to switch to drugs with less secondary effects or to add adjuvant medications to improve the overall evolution of these patients.
author	Rojas G,Paula Poblete A,Catalina Orellana G,Ximena Rouliez A,Karen Liberman G,Claudio
author_facet	Rojas G,Paula Poblete A,Catalina Orellana G,Ximena Rouliez A,Karen Liberman G,Claudio
author_sort	Rojas G,Paula
title	Alteraciones metabólicas asociadas al uso de terapia antipsicótica
title_short	Alteraciones metabólicas asociadas al uso de terapia antipsicótica
title_full	Alteraciones metabólicas asociadas al uso de terapia antipsicótica
title_fullStr	Alteraciones metabólicas asociadas al uso de terapia antipsicótica
title_full_unstemmed	Alteraciones metabólicas asociadas al uso de terapia antipsicótica
title_sort	alteraciones metabólicas asociadas al uso de terapia antipsicótica
publisher	Sociedad Médica de Santiago
publishDate	2009
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100017
work_keys_str_mv	AT rojasgpaula alteracionesmetabolicasasociadasalusodeterapiaantipsicotica AT pobleteacatalina alteracionesmetabolicasasociadasalusodeterapiaantipsicotica AT orellanagximena alteracionesmetabolicasasociadasalusodeterapiaantipsicotica AT rouliezakaren alteracionesmetabolicasasociadasalusodeterapiaantipsicotica AT libermangclaudio alteracionesmetabolicasasociadasalusodeterapiaantipsicotica
_version_	1718436423026081792

Alteraciones metabólicas asociadas al uso de terapia antipsicótica

Ejemplares similares